Fundz
Real-time · AI · Cross-signal

Locus Cell just moved. Here's exactly what to do next.

Who to reach, what to say, and why now — on Locus Cell, plus every contract, funding round, and exec hire that follows, each with verified, ICP-ranked contacts.

Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.

Get the full Deep Dive on Locus Cell — free.

We'll email your report. No spam; unsubscribe anytime.

Ready now? Choose your plan · Request a demo · Sign in

▶
Watch the 2-minute tour · with sound
Don’t take our word for it — ask the live AI about Locus Cell, free
Try the live AI on Locus Cell — no signupNo signup to start
Your turn — ask anything about Locus Cell and hit Ask. Your first answer is free, no signup.
Tap one:

Locus Cell Partners with Cambium Bio for Phase III CDMO Manufacturing of Elate Ocular®.

Sep 29, 2025•8 months ago

Contract Type

partnership

TaiwanManufacturingBiotechnology

Description

Locus Cell has signed a Memorandum of Understanding with Cambium Bio for the contract development and manufacturing of Elate Ocular® related therapies. This partnership marks Locus Cell's first Phase III international CDMO project, enhancing their role in global pharmaceutical manufacturing.

Company Information

Company

Locus Cell

Location

Taiwan

About

Locus Cell is a leading regenerative medicine contract development and manufacturing organization (CDMO) based in Taiwan. The company specializes in providing innovative solutions for pharmaceutical and biotechnology partners. It boasts state-of-the-art facilities that comply with international regulatory standards, including FDA requirements.

Predictive Intelligence
Strategic

ML-powered predictions for Locus Cell's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.